Emerging role of apelin as a therapeutic target in cancer: A patent review

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 367-372

  Rayalam, Srujana ^a   Della Fera, Mary A ^a   Kasser, Thomas ^b   Warren, William ^c   Baile, Clifton A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Angionics Inc   (United States)

^c Sutherland Asbill and Brennan LLP   (United States)

Author keywords

Angiogenesis; Angiogenic inhibitors; Apelin; Cancer; Lymphangiogenesis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; APELIN; BEVACIZUMAB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BREAST CANCER; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; KIDNEY CANCER; LUNG CANCER; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PATENTS AS TOPIC;

EID: 80052326129     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957856     Document Type: Review

References (70)

1. Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP. Bevacizumab in the treatment of breast cancer. Cancer Treat Rev 2010; 36(1): 75-82.
2. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13(1): 31-36.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82(1): 4-6.
4. Muthukkaruppan VR, Kubai L, Auerbach R. Tumor-induced neovascularization in the mouse eye. J Natl Cancer Inst 1982; 69(3): 699-708.
5. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18.
6. Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim Biophys Acta 2006; 1765(2): 155-177.
7. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251(2): 471-476.
8. Suenaga, M., Ito, T., Nishimura, O. Process for producing apelin. WO00036122 (2000).
9. Matsumoto, H., Noguchi, J., Hinuma, S. Use of apelin. WO03063892 (2003).
10. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: Tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538(2-3): 162-171.
11. Kalin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007; 305(2): 599-614.
12. Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, et al. Apelin, the natural ligand of the orphan seventransmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol 2000; 74(24): 11972-11976.
13. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136(1-2): 355-360.
14. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et al. Orphanin FQ: A neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995; 270(5237): 792-794.
15. Hinuma, S., Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kitada, C. Polypeptide, their production and use. WO99033976 (1999).
16. Hinuma, S., Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kitada, C. APJ ligand polypeptides. US6492324 (2002).
17. Hinuma, S., Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kitada, C. Polypeptides, their production and use. US7410776 (2008).
18. Devic E, Paquereau L, Vernier P, Knibiehler B, Audigier Y. Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev 1996; 59(2): 129-140.
19. Devic E, Rizzoti K, Bodin S, Knibiehler B, Audigier Y. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 1999; 84(1-2): 199-203.
20. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296(1): 177-189.
21. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001; 132(6): 1255-1260.
22. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84(5): 1162-1172.
23. Risau W. Mechanisms of angiogenesis. Nature 1997; 386(6626): 671-674.
24. Takakura N, Kidoya H. Maturation of blood vessels by haematopoietic stem cells and progenitor cells: Involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation. Thromb Haemost 2009; 101(6): 999-1005.
25. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. Embo J 2008; 27(3): 522-534.
26. Ashley E, Chen MM, Quertermous T, Deng DX-F, Tsalenko A, Ben-dor A, Bruhn, L., Yakhini, Z. Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof. US20050152836 (2005).
27. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98(6): 1335-1342.
28. Shijubo N, Uede T, Kon S, Nagata M, Abe S. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000; 11(2): 135-146.
29. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002; 296(5574): 1883-1886.
30. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285(21): 1182-1186.
31. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353-364.
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362(6423): 841-844.
33. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5(12): 1359-1364.
34. Shojaei F, Ferrara N. Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 2007; 87(3): 227-230.
35. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
36. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5): 427-434.
37. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792-799.
38. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438(7070): 946-953.
39. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC, Harris AL, et al. LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 2005; 58(2): 202-206.
40. Rouzaut A, Irigoyen M, Montuenga LM. Lymphangiogenesis and lung cancer. J Thorac Oncol 2007; 2(5): 384-386.
41. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, Talmadge JE, et al. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 2005; 65(19): 9004-9011.
42. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63(3): 713-722.
43. Schmidt, M., Bagri, A. Methods and compositions for diagnostic use for tumor treatment. US20100029491 (2010).
44. Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev 2002; 110(1-2): 183-186.
45. Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, Soubrier F. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008; 103(4): 432-440.
46. Krieg, P.A. Methods for modulating angiogenesis with apelin compostions. EP1613348 (2010).
47. Krieg, P.A. Methods for modulating angiogenesis with apelin compositions. US7736646 (2010).
48. Krieg, P.A. Methods for modulating angiogenesis and apoptosis with apelin compositions. WO2006023893 (2006).
49. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264(5158): 569-571.
50. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 1996; 40(6): 1189-1197.
51. Wilting J, Christ B, Bokeloh M. A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Studies on the effects of carriers, PBS, angiogenin, and bFGF. Anat Embryol (Berl) 1991; 183(3): 259-271.
52. Krieg, P.A. Metods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions. WO2006076736 (2006).
53. St Croix, B., Seaman, S. Differential gene expression in physiological and pathological angiogenesis. WO2008057632 (2008).
54. Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y. Apelin is a potent activator of tumour neoangiogenesis. Oncogene. 2007; 26(55): 7692-7699.
55. Wang Z, Greeley GH, Jr., Qiu S. Immunohistochemical localization of apelin in human normal breast and breast carcinoma. J Mol Histol 2008; 39(1): 121-124
56. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer cell 2007; 11(6): 539-554.
57. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, et al. Apelin expression in human non-small cell lung cancer: Role in angiogenesis and prognosis. J Thorac Oncol 2010; 5(8): 1120-1129.
58. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008; 68(14): 5501-5504.
59. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: Vasoactive mechanisms and inotropic action in disease. Hypertension 2009; 54(3): 598-604.
60. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007; 101(4): e32-e42.
61. Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY, et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 2009; 297(5): H1904-H1913.
62. Rayalam S, Della-Fera MA, Krieg PA, Cox CM, Robins A, Baile CA. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun 2008; 368(3): 815-819.
63. Bevec, D., Cavalli, F., Cavalli, V., Bacher, G. Use of apelin-13 (QRPRLSHKGPMPF) and optionally alpha-casein (90-96) as a therapeutic agents in EG the treatment of HIV infection. WO2009033784 (2009).
64. Fujii, R. Novel application of apelin. US20090233854 (2009).
65. Braiman-Wiksman, L., Solomonik, I. Methods for accelerating wound healing by administration of adipokines. US7638484 (2009).
66. Bevec, D., Cavalli, F., Cavalli, V., Bacher, G. Use of apelin-12 as a therapeutic agent, EG for treating excessive angiogenesis. WO2009046824 (2009).
67. Janz, J., Kuliopulos, A., McMurry, T.J. APJ receptor compounds. WO2010053545 (2010).
68. Soubrier, F., Eyries, M. Methods for the treatment and the diagnosis of pulmonary arterial hypertension. WO2010115874 (2010).
69. Clark, E., Grenfell-Lee, T., Lu, K., Hartmann, L., Brown, J.L. Compositions and methods for the identification, assessment, prevention and therapy of human cancers. US7338758 (2008).
70. Neamati, N. Novel compounds for treatment of cancer and disorders associated with angiogenesis function. US20100120781 (2010).